DIPSS Plus Score

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

Overview

Dynamic International Prognostic Scoring System (DIPSS)‐plus scoring system comprises of eight risk variables to predict the prognosis in myelofibrosis.

DIPSS Plus Score Calculator

DIPSS plus score for prognosis in myelofibrosis

This handy calculator computes the prognosis in myelofibrosis using Dynamic International Prognostic Scoring System (DIPSS)‐plus. This scoring system comprises of eight risk variables.^[1]^[2]

Check all boxes that apply to your patient:

Interpretation of DIPSS plus score

Score = 0: Low risk group; estimated median survival is approximately 15.4 years
Score = 1: Intermediate-1 risk group; estimated median survival is approximately 6.5 years
Score = 2 or 3: Intermediate-2 risk group; estimated median survival is approximately 2.9 years
Score ≥ 4: High risk group; estimated median survival is approximately 1.3 years

References

↑ Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A (February 2011). “DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status”. J. Clin. Oncol. 29 (4): 392–7. doi:10.1200/JCO.2010.32.2446. PMID 21149668.
↑ Bose P, Verstovsek S (August 2016). “Prognosis of Primary Myelofibrosis in the Genomic Era”. Clin Lymphoma Myeloma Leuk. 16 Suppl: S105–13. doi:10.1016/j.clml.2016.02.031. PMC 4987499. PMID 27521306.

[pmid21149668-1] Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A (February 2011). “DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status”. J. Clin. Oncol. 29 (4): 392–7. doi:10.1200/JCO.2010.32.2446. PMID 21149668.

[pmid27521306-2] Bose P, Verstovsek S (August 2016). “Prognosis of Primary Myelofibrosis in the Genomic Era”. Clin Lymphoma Myeloma Leuk. 16 Suppl: S105–13. doi:10.1016/j.clml.2016.02.031. PMC 4987499. PMID 27521306.

[1]

[2]

DIPSS Plus Score for Prognosis in Myelofibrosis
Variable	Score
Age >65 years	1
Constitutional symptoms	1
Hemoglobin <10 g/dL	1
Leucocyte count >25 x 10⁹/L	1
Circulating blasts ≥1%	1
Unfavourable karyotype (complex karyotype or abnormalities that include +8, -7/7q-, i(17q), inv(3), 5/5q-, 12p-, or 11q23 rearrangement)	1
Transfusion dependency	1
Platelet count <100 x 10⁹/L	1
DIPSS Plus Score:
Interpretation: